Conclusions: This is the first study to demonstrate that higher BMD in men and women is associated with tibiofemoral cartilage loss on MRI in knees without RKOA, including K-L grade 0 knees. We also confirm previous findings from radiographs in this cohort that BMD is weakly, or not all, associated with structural progression in knees with existing RKOA. 
PREVENTION OF KNEE OSTEOARTHRITIS IN OVERWEIGHT FEMALES; FROM FEASIBILITY TRIAL TO FULL-SCALE TRIAL

Purpose:
In the present study we will test the preventive effect of a tailor made intervention for reducing weight as well as of an intervention with oral crystalline glucosamine sulphate in a factorial design in a high-risk group of overweight middle aged women who have not yet consulted for knee osteoarthritis (OA). Methods: 40 general practitioners (GPs) will contact all registered women between 50 and 60 years of age without major co-morbidities. After telephonic screening, 400 women with a BMI 27 who have not yet consulted for knee pain will be included in this study. At baseline, X-rays and MRIs will be made of both knees to measure presence and amount of OA features. Presence of radiological signs indicating knee OA (KellgrenLawrence index of 2 or more) and knee OA according to the ACR criteria are exclusion criteria. From serum and urine samples serum glucose, serum cholesterol, levels of bone and cartilage degeneration markers and inflammation markers will be determined. Through physical examination weight, length, blood pressure, skin fold, pain on pressure of the joint margins, and crepitation of the knee joint will be measured. All participants fill in a questionnaire to measure knee complaints (WOMAC), activity level (SQUASH), menopausal status, co-morbidity, medical consumption, cointerventions, and quality of live (Euroqol). After baseline measurements, participants will be randomised over four groups. Half of all participants will be allocated to a tailor made intervention of half a year to reduce weight (consisting of physical activity classes and several consultations with a dietician); the other half will not receive this intervention. Secondly, in both groups half of the participants will be randomised to receive 1500 mg oral crystalline glucosamine sulphate once a day for two and a half year while the other half will receive a placebo. After two and a half year, baseline measurements will be repeated. The full-scale trial was preceded by a pilot trial. In this feasibility trial procedures, compliance and effects of the intervention were tested during a one year follow-up. Results: 1365 women were contacted by 10 GPs. Of these 353 women returned a response to our research centre (26%). 184 were excluded after telephonic screening because they did not meet the inclusion criteria (52%). Of the remaining 93 (55%) were willing to participate and were included in the study and followed for one year according the abovementioned protocol. After 6 months, 89% of the participants had taken more than 75% of the glucosamine or placebo. At the end of the feasibility study, 73% of the women allocated to the tailor made intervention have visited the physical activity classes and 84% of them had al least one consultation with the dietician. 28% of the women in the weight reduction group showed a weight reduction of 5 kg and/or 5% reduction of the baseline weight versus 13% in the other group. At one year, only 4% is lost to followup. On the baseline MRIs, 20% of the women showed osteochondral defects on the patella and 10% on the medial and lateral condyle of the femur. Osteophytes were found on the patella and on the lateral and medial condyle of the femur (all in 10% of the women). Over 50% of the women showed degeneration of the medial meniscus and 35% of the lateral meniscus. At one year follow-up, 5% of the cases or less showed progression of the knee OA related features on the MRIs. Conclusions: Based on the results of the pilot trial, a full-scale trial seems to be feasible. Therefore all participants of the pilot trial will be followed for another one and a half year and 307 new participants will be gathered according to above-mentioned protocol. Purpose: The objective of our study was to explore the (OA) of the knee, hip, hand, and in vertebral OA. Methods: We performed a retrospective study involving 497 patients who did receive a chondroprotective treatment [Glucosamine 500 mg + Chondroitin-sulphate (CSbBio-Active TM ) 500 mg), and native collagen type II (1 mg) once a day] for their painful osteoarthritis during 12 months. Knee OA was present in 234 pts, hip OA in 78, hand OA in 124, cervical OA in 26 and lumbar OA in 35 pts. For defining treatment adherence levels, a self reported information recorded on patient's file was examined and a cut-off of 70% was established.
Adherence to chondroprotective treatment in OA.
Results: During the 12 months of observation, the level of adherence >70% was maintained for 22/78 of hip OA, 185/234 for knee OA, 10/26 for cervical OA, 15/35 for lumbar OA and 98/124 for hand OA; the overall number of adherents was 330 and 167 discontinued the chondroprotective treatment. Patients affected with peripheral OA did maintain the >70% treatment adherence greater than pts with vertebral OA (p > 0.01). The difference between hip sufferers and knee sufferers was significant. The difference between hand and knee sufferers was not significant. Conclusions: People who are prescribed self-administered medications generally take less than the prescribed doses. Increasing adherence to medications might improve the benefits, but also might increase adverse effects of medications. This is not the case of chondroprotective treatment, which has in toxicology studies an excellent tolerance profile. In our observation, a quite satisfactory adherence was present only in sufferers of knee OA and hand OA. Ameliorating adherence may possibly improve patient outcomes.
THE VECTRA STUDY: ECONOMIC AND HEALTH
ASSESSMENT OF CHONDROITIN SULFATE FOR OSTEOARTHRITIS TREATMENT
C. Rubio. Health value, Madrid, SPAIN
Purpose: To estimate the average cost per patient with osteoarthritis, treated with CS or NSAID for 6 months, and the possible consequences that the reduction on the consumption of NSAID due to CS treatment may have on the budget impact for the Spanish National Health System (NHS).
